Clinical trials: Arthritis, Juvenile Rheumatoid
Myocarditis, ANCA Associated Vasculitis
EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases
Inflammatory Cardiovascular Diseases and Autoimmune Rheumatic Diseases (ICARDs) encompass cardiovascular involvement in connective tissue diseases, vasculitis, and primary inflammatory cardiac processes affecting all layers of…
- Conditions
- Myocarditis, ANCA Associated Vasculitis, Pericarditis, Systemic Sclerosis
- Trial name
- EACVI-INFLAME (NCT07077304)
- Testing
- observational study
- Where
- France
- Volunteers
- 5,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Systemic Juvenile Idiopathic Arthritis (SJIA)
ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab
The purpose of this study was to evaluate the efficacy observed with canakinumab dose reduction in a subgroup of patients in the extension study CACZ885G2301E1.
- Trial name
- ß-SPECIFIC 4 (NCT02296424)
- Testing
- ACZ885 150 mg (Canakinumab)
- Where
- 50 sites in United States, Austria and 14 more
- Volunteers
- 182 people
- Sponsor
- Novartis Pharmaceuticals
Juvenile Rheumatoid Arthritis
Infliximab to Treat Children With Juvenile Rheumatoid Arthritis
This study will determine whether a stepwise increase of the drug infliximab (Remicade® (Registered Trademark)) controls juvenile rheumatoid arthritis more effectively than a fixed dose.
- Trial name
- NCT00029042
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Arthritis, Juvenile Rheumatoid
Identification of Genes Involved in Juvenile Idiopathic Arthritis by Wholel Exome Sequencing
Juvenile idiopathic arthritis (JIA) is considered to be a multifactorial disease caused by a combination of environmental factors and predisposing genetic factors.
- Trial name
- GenesinJIA (NCT02067962)
- Testing
- Blood sample
- Volunteers
- 30 people
- Sponsor
- University Hospital, Montpellier
Arthritis, Arthritis, Juvenile Idiopathic
Pain in Inflammatory Joint Diseases
Our primary objective is to better understand the etiology and consequences of chronic paint by using an explorative approach to identify phenotypes and endotypes of patients with inflammatory joint diseases, with a special focus…
- Conditions
- Arthritis, Arthritis, Juvenile Idiopathic, Arthritis,Rheumatoid, Arthritis, Reactive
- Trial name
- Nor-Pain (NCT06718569)
- Testing
- Biological or targeted synthetic DMARD
- Where
- Norway
- Volunteers
- 350 people
- Sponsor
- Diakonhjemmet Hospital
Juvenile Idiopathic Arthritis
UCAN CAN-DU: Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease
Childhood arthritis is a chronic disabling disease. New medications called biologic therapies are now available to treat arthritis that target key biologic molecules that cause inflammation.
- Trial name
- UCAN CAN-DU (NCT06560606)
- Where
- 19 sites in Canada, Netherlands
- Volunteers
- 4,100 people
- Sponsor
- The Hospital for Sick Children
Still's Disease, Adult-Onset, Systemic Inflammation
Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, and Related Conditions
Background: Inflammatory conditions can cause symptoms like fevers, arthritis, and rash. Systemic juvenile idiopathic arthritis (sJIA) is one of these conditions. So is adult-onset Still s disease (AOSD).
- Conditions
- Still's Disease, Adult-Onset, Systemic Inflammation, Arthritis, Autoinflammatory Syndrome
- Trial name
- NCT03510442
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Arthritis, Psoriatic, Arthritis, Rheumatoid
Study Evaluating Etanercept in Patients With Rheumatoid Arthritis(RA), Juvenile Idiopathic Arthritis (JIA), or Psoriatic Arthritis (PsA) in Spain
The purpose of this study is to assess the safety of etanercept in patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) or psoriatic arthritis (PsA) in Spain
- Trial name
- NCT00195377
- Testing
- Etanercept
- Where
- Spain
- Volunteers
- 1,000 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Juvenile Rheumatoid Arthritis
Supplementation With Vitamin D, Calcium or Both on Calcium Absorption and Bone Mineral Content in Children With JRA
2000 international units (IU) vitamin D, 1 gram (gm) calcium, or both given to children with Juvenile Rheumatoid Arthritis (JRA) may increase percent true calcium absorption, bone mineral turnover and/or bone mineralization.
- Trial name
- NCT00570934
- Testing
- Cholecalciferol, Calcium, Calcium and cholecalciferol
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Missouri-Columbia
Arthritis, Juvenile Rheumatoid
Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA)
To obtain safety, efficacy, pharmacokinetic and dosing information for meloxicam oral suspension in children with Juvenile Rheumatoid Arthritis (JRA)
- Trial name
- NCT00034853
- Testing
- meloxicam oral suspension, naproxen oral suspension
- Where
- 37 sites in United States, Brazil and 2 more
- Volunteers
- 180 people
- Sponsor
- Boehringer Ingelheim
Arthritis, Juvenile Rheumatoid
Juvenile Inflammatory Rheumatism (JIR) Cohorte
The investigators created a cohort of patients with juvenile inflammatory rheumatisms with the purpose to follow them prospectively, and investigate the tolerance and efficacy of immunosuppresive and biological agents.
- Trial name
- JIR-cohorte (NCT02377245)
- Where
- 45 sites in Belgium, France and 3 more
- Volunteers
- 15,000 people
- Sponsor
- Michaël Hofer
Rheumatic Joint Disease
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies.
- Trial name
- NCT02418442
- Where
- 82 sites in United States, Canada and 3 more
- Volunteers
- 20,000 people
- Sponsor
- Duke University
Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic
A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)
Macrophage Activation Syndrome (MAS) is a rare, life-threatening condition characterized by uncontrolled hyperinflammation which may develop on the background of systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset…
- Conditions
- Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic, Arthritis, Juvenile, Adult Onset Still Disease
- Trial name
- NCT03311854
- Testing
- Emapalumab
- Where
- 5 sites in United States, France and 3 more
- Volunteers
- 14 people
- Sponsor
- Swedish Orphan Biovitrum
Arthritis, Juvenile Rheumatoid
Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis
This multi-center observational Registry will collect long-term safety data on patients treated with celecoxib or non-selective nonsteroidal anti-inflammatory drugs (nsNSAIDs) as used in clinical practice for the treatment of…
- Trial name
- SINCERE (NCT00688545)
- Testing
- Celecoxib, nsNSAIDs
- Where
- 27 sites in United States
- Volunteers
- 275 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Juvenile Idiopathic Arthritis
PEAK Study (Physical Exercise and Activity in Kids)
The objectives of this study are to study the effect of formal exercise training on motor function and overall physical fitness in children with arthritis. A 12-week comprehensive exercise program will be used.
- Trial name
- NCT00213187
- Testing
- Aerobic and Qi gong Exercise
- Where
- Canada
- Volunteers
- 80 people
- Sponsor
- The Hospital for Sick Children
Rheumatic Diseases, Rheumatic Disorder
Exploring and Measuring the Impact of Steroids in Children and Young People
Assessing the impact of glucocorticoids in children and young people with rheumatic conditions, to develop a patient reported outcome measure (PROM).
- Conditions
- Rheumatic Diseases, Rheumatic Disorder, Rheumatologic Conditions (JRA,Lupus)
- Trial name
- NCT07350395
- Where
- 3 sites in United Kingdom
- Volunteers
- 70 people
- Sponsor
- University of the West of England
Systemic Juvenile Idiopathic Arthritis
Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)
This study assessed the initial efficacy and safety of canakinumab over a 4 week period in patients with systemic juvenile idiopathic arthritis (SJIA) having a flare.
- Trial name
- β-SPECIFIC 1 (NCT00886769)
- Testing
- Canakinumab
- Where
- 91 sites in United States, Argentina and 20 more
- Volunteers
- 84 people
- Sponsor
- Novartis Pharmaceuticals
Arthritis, Juvenile Idiopathic
Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis
This study will evaluate the effect of etanercept on the clinical benefit, safety, and physical functioning (ability to function in daily life) in children and adolescent subjects with 3 subtypes of childhood arthritis.
- Trial name
- CLIPPER (NCT00962741)
- Testing
- Etanercept
- Where
- 42 sites in Australia, Belgium and 17 more
- Volunteers
- 127 people
- Sponsor
- Pfizer
Arthritis, Juvenile Rheumatoid
A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA
To study Celebrex versus naproxen to see if it decreases symptoms of juvenile arthritis such as pain and swelling.
- Trial name
- NCT00652925
- Testing
- Celecoxib, Naproxen
- Where
- 58 sites in United States, Belgium and 13 more
- Volunteers
- 225 people
- Sponsor
- Pfizer
Arthritis, Juvenile Rheumatoid
A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA)
A one year double-blind trial to investigate the efficacy and safety of meloxicam oral suspension 0.25 mg/kg and 0.125 mg/kg administered once daily in comparison to naproxen oral suspension 5 mg/kg administered twice daily in…
- Trial name
- NCT00279747
- Testing
- meloxicam 0.25 mg/kg, meloxicam 0.125 mg/kg, naproxen 10 mg/kg
- Where
- 34 sites in Austria, Belgium and 5 more
- Volunteers
- 226 people
- Sponsor
- Boehringer Ingelheim